

# Alaska HB 228 Psychedelic Medicine Task Force

**Task Force Meeting #6 | Tuesday, April 29, 2025 | 5:15 – 7:00 pm**

## Meeting Objectives

- Conduct public hearing and hear public testimony on draft recommendations.
- Discuss next steps for Task Force process, including voting on recommendations and final report.

## Meeting Agenda

Time	Item	Lead
5:15 pm	<ul style="list-style-type: none"><li>• Call to Order</li><li>• Roll Call of Members; Member Disclosures</li><li>• Approve Meeting Agenda (<b>vote</b>)</li><li>• Approve Prior Meeting Notes (<b>vote</b>)</li></ul>	<i>Co-Chairs</i> <i>Task Force Staff</i> <i>Co-Chairs</i>
5:25 pm	<b>Reminders for Task Force Members</b> <ul style="list-style-type: none"><li>• Public comment process</li><li>• Regarding protected health information (PHI)</li></ul>	<i>Facilitator</i>
5:30 pm	<b>Public Hearing: Opportunity for Testimony</b> <ul style="list-style-type: none"><li>• Individuals in the room (Juneau)</li><li>• Individuals on phone (Legis. Teleconference Syst.)</li></ul>	<i>Co-Chairs + Facilitator</i>
~6:30 pm <i>Will begin after last testifier, timing TBD.</i>	<b>Group Debrief on Comments; Process Discussion</b> <ul style="list-style-type: none"><li>• Initial reflections on written and verbal comments</li><li>• Discuss process next steps:<ul style="list-style-type: none"><li>○ Revisions and additional work on report draft</li><li>○ Voting on recommendations, final report</li></ul></li></ul>	<i>Group discussion</i>
6:50 pm	<b>Wrap Up and Next Steps</b> <ul style="list-style-type: none"><li>• Public comment closes Monday, May 5, 2025!</li><li>• Review action items for members &amp; staff</li><li>• Member Closing Comments</li></ul>	<i>Co-Chairs &amp; Facilitator</i> <i>All Task Force Members</i>
7:00 pm	Adjourn	<i>Co-Chairs</i>

## Instructions and Reminders for Public Testimony

- Please state your full name, location, and any affiliation or organization you are representing, for the public record.
- Testimony will be limited to 3 minutes per person.
- Testifiers are encouraged to also submit their testimony and any additional materials in writing to [sen.forrest.dunbar@akleg.gov](mailto:sen.forrest.dunbar@akleg.gov) and [rep.justin.ruffridge@akleg.gov](mailto:rep.justin.ruffridge@akleg.gov).
- Because this topic may relate to protected health information (PHI), keep the following in mind:
  - A person's health information is protected by federal law (HIPAA), including medical history, diagnoses, prescription medications, and other identifying information.
  - A person who testifies or provides comments in writing is sharing this information on the public record, and will be considered to have waived their right to confidentiality for any information shared on the record, including if the person chooses to disclose PHI.
  - A person cannot waive the right to confidentiality of PHI for another person, including if that person is a spouse or family member. Do not share another person's PHI.

## Task Force Resources

### Task Force Purpose (HB 228, passed 2024)

Purpose: To prepare for potential medicalization of psychedelic medicines by U.S. FDA; to make policy recommendations to the Alaska Legislature concerning insurance and licensure, given the unique nature of the administration of psychedelic medicines; and to ensure the state is prepared if psychedelic medicines become available for prescription.

- (1) assess potential use of psychedelic medicine in addressing Alaska's mental health crisis;
- (2) consider barriers to implementation and equitable access;
- (3) consider and recommend licensing and insurance requirements for practitioners in the state if psychedelic medicines are federally reclassified and approved by the FDA; and
- (4) consider legal and regulatory changes that could be necessary in the state after federal medical approval of psychedelic medicines.

### Full Bill Text and Documents

*Alaska House Bill 228: An act establishing the Alaska task force for the regulation of psychedelic medicines approved by the United States Food and Drug Administration; effective date. (2024)*

<https://www.akleg.gov/basis/Bill/Detail/33?Root=hb228>

### Background Reading

*NOTE: These publications and their findings are provided for information only, and do not represent the positions or recommendations of the Task Force, or any organization represented on the Task Force.*

- Minnesota Psychedelic Medicine Task Force, Final Report to the Legislature, January 2025. <https://www.health.state.mn.us/people/psychmed/docs/legreport.pdf>
- Siegel, J. S., Daily, J. E., Perry, D. A., & Nicol, G. E. (2023). Psychedelic Drug Legislative Reform and Legalization in the US. *JAMA psychiatry*, 80(1), 77–83. <https://doi.org/10.1001/jamapsychiatry.2022.4101>
- Smith, W. R., & Appelbaum, P. S. (2022). Novel ethical and policy issues in psychiatric uses of psychedelic substances. *Neuropharmacology*, 216, 109165. <https://doi.org/10.1016/j.neuropharm.2022.109165>
- McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., ... Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. *JAMA network open*, 7(6), e2414650. <https://doi.org/10.1001/jamanetworkopen.2024.14650>
- Jacobs, E., Earp, B. D., Appelbaum, P. S., Bruce, L., Cassidy, K., Celidwen, Y., Cheung, K., Clancy, S. K., Devenot, N., Evans, J., Lynch, H. F., Friesen, P., Romeu, A. G., Gehani, N., Maloof, M., Marcus, O., Martin Moen, O., Mertens, M., Nayak, S. M., Noorani, T., ... Yaden, D. B. (2024). The Hopkins-Oxford Psychedelics Ethics (HOPE) Working Group Consensus Statement. *The American journal of bioethics : AJOB*, 24(7), 6–12. <https://doi.org/10.1080/15265161.2024.2342764>